Method of recognizing abnormal tissue using the detection of early increase in microvascular blood content

• US 20070179368A1
• Filed: 11/27/2006
• Published: 08/02/2007
• Est. Priority Date: 10/27/2005
• Status: Abandoned Application

• Current Assignee: Northshore University Healthsystem (Advocate Aurora Health, Inc.)
• Original Assignee: Evanston Northwestern Healthcare Corporation, Northwestern University
• Inventors: Kim, Young, Backman, Vadim, Roy, Hemant, Turzhitsky, Vladimir, Siegel, Michael, Wali, Ramesh
• Application Number:
  US11/604,653
• Publication Number:
  US 20070179368A1
• Time in Patent Office: Days
• US Class Current: 600/315
• CPC Class Codes: A61B 5/0075 by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy A61B5/0071 takes precedence
• CPC Class Codes: A61B 5/0084 for introduction into the body, e.g. by catheters A61B5/1459 takes precedence
• CPC Class Codes: A61B 5/0091 for mammography
• CPC Class Codes: A61B 5/0261 using optical means, e.g. infrared light
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence

Abstract

The present invention, in one aspect, relates to a method for examining a target for tumors or lesions using what is referred to as “Early Increase in microvascular Blood Supply” (EIBS) that exists in tissues that are close to, but are not themselves, the abnormal tissue and in tissues that precede the development of such lesions or tumors. While the abnormal tissue can be a lesion or tumor, the abnormal tissue can also be tissue that precedes formation of a lesion or tumor, such as a precancerous adenoma, aberrant crypt foci, tissues that precede the development of dysplastic lesions that themselves do not yet exhibit dysplastic phenotype, and tissues in the vicinity of these lesions or pre-dysplastic tissues.

Claims

1. A method of providing an indication that living tissue of a body may be abnormal comprising the steps of:

inserting an illumination probe such that a light source within the illumination probe is disposed in a location that is at a surface of an organ;

illuminating, at the location, tissue of the organ and microvasculature therein with light from the light source that is emitted from the illumination probe, wherein the tissue that is illuminated with the light does not contain the living tissue that may be abnormal;

detecting interacted light that results from the step of illuminating the tissue as detected data, wherein the interacted light is obtained substantially from the light that then interacts with blood in the microvasculature that is within the tissue of the organ, which tissue does not contain the living tissue that may be abnormal;

estimating at least one of blood content and blood flow in the microvasculature using the detected data; and

obtaining the indication that the living tissue may be abnormal using the at least one of estimated blood content and blood flow, the step of obtaining including the step of determining whether there exists an increase in the at least one of estimated blood content and blood flow in the microvasculature.

2. The method according to claim 1 wherein the organ contains the living tissue for which the indication is being obtained.

3. The method according to claim 1 wherein another organ contains the living tissue for which the indication is being obtained, and the another organ is different from the organ containing the tissue that is illuminated in the step of illuminating.

4. The method according to claim 1 wherein the interacted light in the step of detecting is obtained from the light that is scattered by the blood in the microvasculature.

5. The method according to claim 1 wherein the interacted light in the step of detecting is obtained from the light that is scattered and absorbed by the blood in the microvasculature.

6. The method according to claim 1 wherein the interacted light in the step of detecting is obtained from the light that is absorbed by the blood in the microvasculature.

7. The method according to claim 1 wherein the living tissue is a precancerous living tissue that may be abnormal.

8. The method according to claim 7 wherein the precancerous living tissue that may be abnormal is a predysplastic stage tissue.

9. The method according to claim 8 wherein the predysplastic stage tissue is at least one of histologically normal, macroscopically normal, and endoscopically normal.

10. The method according to claim 1 wherein the step of inserting the illumination probe inserts the probe into the organ, such that the surface of the organ is an inner surface of the organ.

11. The method according to claim 10 wherein the organ is the colon.

12. The method according to claim 10 wherein the organ is one of the stomach, the duodenum, the bladder, the esophagus, the oral cavity and the lung.

13. The method according to claim 10 wherein the organ is one of the uterus, the urethra and the prostate.

14. The method according to claim 1 wherein the step of detecting detects at least one of the following components of the interacted light:

co-polarized, cross-polarized, and unpolarized interacted light.

15. The method according to claim 14 wherein the step of estimating estimates blood content.

16. The method according to claim 15 wherein the step of estimating the blood content estimates a concentration of red blood cells.

17. The method according to claim 15 wherein the step of estimating the blood content estimates a concentration of hemoglobin.

18. The method according to claim 15 wherein the step of estimating the blood content estimates a concentration of de-oxygenated hemoglobin.

19. The method according to claim 15 wherein the step of estimating the blood content estimates a concentration of oxygenated hemoglobin.

20. The method according to claim 15 wherein the step of estimating the blood content estimates one of blood flow and a rate of blood flow.

21. The method according to claim 15 wherein the step of estimating the blood content estimates oxygen saturation in the blood.

22. The method according to claim 14 wherein the step of estimating one of the blood content and the blood flow estimates a statistic of blood content or blood flow with an area of the living tissue.

23. The method according to claim 22 wherein the statistic is one of mean, average, median, standard deviation, maximal value, and minimal value.

24. The method according to claim 14 wherein the step of detecting detects interacted light from the surface to a submucosal layer.

25. The method according to claim 14 wherein the step of detecting the tissue detects interacted light from the surface to a mucosal layer.

26. The method according to claim 1 wherein the steps of inserting, illuminating and detecting are performed during a same period of time when a screening colonoscopy is performed.

27. The method according to claim 1 wherein the steps of inserting, illuminating and detecting are performed during a same period of time when a sigmoidoscopy is performed.

28. The method according to claim 1 wherein the steps of inserting, illuminating and detecting are performed using a stand-alone probe.

29. The method according to claim 1 wherein the steps of inserting, illuminating and detecting are performed using a probe disposed at least partially within an endoscopic device.

30. The method according to claim 1 wherein the step of inserting the probe inserts the probe adjacent to the organ, such that the surface of the organ is an outer surface of the organ.

31. The method according to claim 30 wherein the step of inserting the probe inserts the probe into a small bowel, adjacent to a pancreas, to detect the abnormal living tissue in the pancreas.

32. The method according to claim 1 wherein the step of obtaining the indication includes the step of comparing the estimated blood content with a baseline blood content.

33. The method according to claim 32 further including the step of establishing the baseline blood content.

34. The method according to claim 33 further including the step of establishing the baseline blood content based upon measurements of blood content of a region surrounding the organ.

35. The method according to claim 33 further including the step of establishing the baseline blood content based upon measurements of blood content of a plurality of bodies other than the body.

36. The method according to claim 33 further including the step of establishing the baseline blood content based upon measurements of blood content of the body.

37. The method according to claim 1 wherein the step of estimating estimates blood content.

38. The method according to claim 37 wherein the step of estimating the blood content estimates a concentration of red blood cells.

39. The method according to claim 37 wherein the step of estimating the blood content estimates a concentration of hemoglobin.

40. The method according to claim 37 wherein the step of estimating the blood content estimates a concentration of de-oxygenated hemoglobin.

41. The method according to claim 37 wherein the step of estimating the blood content estimates a concentration of oxygenated hemoglobin.

42. The method according to claim 37 wherein the step of estimating the blood content estimates one of blood flow and a rate of blood flow.

43. The method according to claim 37 wherein the step of estimating the blood content estimates oxygen saturation in the blood.

44. The method according to claim 1 wherein the step of estimating one of the blood content and the blood flow estimates a statistic of blood content or blood flow with an area of the living tissue.

45. The method according to claim 44 wherein the statistic is one of mean, average, median, standard deviation, maximal value, and minimal value.

46. The method according to claim 1 wherein the indication from the step of obtaining indicates that the living tissue may be abnormal at a future point in time.

47. The method according to claim 1 wherein the steps of illuminating, detecting, and estimating are repeated for a plurality of different locations along the surface;

and

wherein the step of obtaining provides a directional indication of a location of the living tissue that may be abnormal based upon at least some of the plurality of different locations.

48. The method according to claim 47 wherein the plurality of different locations are separated by a distance of greater than 5 cm.

49. The method according to claim 47 wherein the plurality of different locations are separated by a distance of greater than 10 cm.

50. The method according to claim 47 wherein the directional indication is provided by a gradient of the indication, in which the indication increases when within 10 cm of the location of abnormal tissue.

51. The method according to claim 50 wherein an area where the gradient is increased indicates an increased likelihood abnormal living tissue.

52. The method according to claim 47, wherein the steps of illuminating and detecting estimating are repeated a plurality of different times.

53. The method according to claim 52 wherein the plurality of different times occur during a single procedure, and the interacted light detected from each of the plurality of different times is normalized together to determine a normalized interacted light that is used in the step of estimating.

54. The method according to claim 47 wherein the step of obtaining the indication includes the step of comparing the estimated blood content with a baseline blood content.

55. The method according to claim 47 wherein the living tissue is a precancerous living tissue that may be abnormal.

56. The method according to claim 55 wherein the precancerous living tissue that may be abnormal is a predysplastic stage tissue.

57. The method according to claim 56 wherein the predysplastic stage tissue is at least one of histologically normal, macroscopically normal, and endoscopically normal.

58. The method according to claim 47 wherein the step of inserting the illumination probe inserts the probe into the organ, such that the surface of the organ is an inner surface of the organ.

59. The method according to claim 58 wherein the organ is the colon.

60. The method according to claim 1 further including the step of using the indication to decide when to perform another test to re-determine whether the living tissue within the organ may be abnormal.

61. The method according to claim 60 wherein the step of using determines when to perform another test using periods of months.

62. The method according to claim 60 wherein the step of using determines when to perform another test using periods of years.

63. The method according to claim 1 wherein the step of estimating uses a polarization and spectral data analysis algorithm.

64. The method according to claim 63 wherein the polarization and spectral data analysis algorithm is a superficial and subsuperficial polarization and spectral data analysis algorithm that estimates blood content.

65. The method according to claim 64 wherein the superficial and subsuperficial polarization and spectral data analysis algorithm is based on a determination of blood content values that show deviation from baseline blood content values that represent normal tissue that does not have an early increase in blood supply.

66. The method according to claim 65 wherein the deviation is recognized by comparing a baseline scattering spectrum that shows the baseline blood content with a spectrum obtained from the detected data using a least squares analysis.

67. The method according to claim 65 wherein the superficial and subsuperficial polarization and spectral data analysis algorithm accounts for exponential attenuation of the interacted light due to presence of the blood in the microvasculature as a function of blood concentration.

68. The method according to claim 64 wherein the step of estimating includes modeling the detected data as a monotonic function of wavelength including at least one of the following:

first-order, second-order, high-order polynomial, and an inverse power-law functions.

69. The method according to claim 68 wherein a model used in the step of modeling ignores an effect of blood absorption in the detected data, and wherein the detected data contains a spectrum of the interacted signal.

70. The method according to claim 64 wherein the step of estimating is performed in substantially real-time.

71. The method according to claim 63 wherein the polarization and spectral data analysis algorithm is a superficial polarization and spectral data analysis algorithm that estimates blood content.

72. The method according to claim 71 wherein the effect of red blood cells is modeled as additive to the rest of the scattering signal.

73. The method according to claim 72 wherein the spectrum of scattering signal without the effect of blood absorption is modeled as a monotonic function of wavelength including at least one of the following:

first-order, second-order, high-order polynomial, and an inverse power-law functions.

74. The method according to claim 63 wherein the polarization and spectral data analysis algorithm is a subsuperficial polarization and spectral data analysis algorithm that estimates blood content.

75. The method according to claim 74 wherein the subsuperficial polarization and spectral data analysis algorithm includes a diffusion approximation.

76. The method according to claim 1 wherein the illuminated tissue is at least one of histologically normal, macroscopically normal, and endoscopically normal.

80. The method according to claim 74 wherein the step of determining uses a non-optical detection to determine whether the early increase in microvascular blood supply exists.

81. The method according to claim 74 wherein the living tissue that may be abnormal is precancerous living tissue.

82. The method according to claim 81 wherein the precancerous living tissue that may be abnormal is a predysplastic stage tissue.

83. The method according to claim 82 wherein the predysplastic stage tissue is histologically normal and microscopically normal.

77. A method of providing an indication that living tissue within an organ of a body may be abnormal comprising the steps of:

identifying tissue of the organ that contains microvasulature therein, wherein the tissue does not contain the living tissue that may be abnormal; and

determining from the blood content within the microvasculature whether an early increase in microvascular blood supply exists in the tissue to indicate whether the living tissue may be abnormal.

78. The method according to claim 77 wherein the step of identifying tissue includes the step of obtaining a biopsy of the tissue.

79. The method according to claim 77 wherein the step of determining uses an optical detection to determine whether the early increase in microvascular blood supply exists.